2nd Sep 2015 11:17
LONDON (Alliance News) - Hutchinson China MediTech Ltd Wednesday said the second proof-of-concept trial of fruquintinib in patients with advanced non-squamous non-small cell lung cancer in China was successful.
"The top-line results demonstrated that the trial clearly succeeded in meeting the primary efficacy endpoint of progression-free survival," said the company.
Fruquintinib is used orally to try to treat refractory tumors such as pancreatic cancer and melanoma, and the company said the second proof-of-concept trial successfully achieved the primary endpoint.
Assessment of secondary efficacy endpoints, including objective response rate, disease control rate, and overall survival is ongoing, with all appearing in-line with expectations, it said.
"The adverse events demonstrated in this proof-of-concept study are consistent with the known safety profile for fruquintinib without major unexpected safety issues. Full detailed results from this trial will be disclosed in due course," said the company.
Hutchinson China shares were down 4.5% to 1,715.00 pence per share on Wednesday afternoon.
By Joshua Warner; [email protected]; @JoshAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed